To conduct a pharmacovigilance analysis using the FDA Adverse Event Reporting System (FAERS) database to evaluate the safety of perfluorohexyloctane ophthalmic solution in treating dry eye disease (DED).
Key Findings:
Verify that all findings are directly sourced from the data without added interpretation.
Interpretation:
Remove the statement regarding major safety concerns.
Limitations:
The study is based on spontaneous reporting, which may not capture all AEs.
Data may be influenced by reporting biases and underreporting of adverse events.
Conclusion:
Remove the suggestion for larger post-marketing studies.
The trilayer decellularized basement membrane is used in ocular surgery and in OSD applications, including corneal and conjunctival-related injuries or defects.
Dr. Theriot discusses the differences between natural tear film and artificial tears—and why the change in moniker to "lubricating drops" is appropriate.
